NDAORALTABLETPriority Review
Approved
Aug 1988
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
3/8 — Basic
Priority Review
THIOLA (tiopronin) by Mission Therapeutics is cystine disulfide reduction [moa]. First approved in 1988.
Drug data last refreshed 16h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
THIOLA (tiopronin) is an oral small-molecule reducing agent that lowers urinary cystine concentration by forming mixed disulfides with cystine, reducing stone formation risk. It is indicated for patients with homozygous cystinuria who are refractory to or intolerant of penicillamine. The drug works by chelating and complexing cystine to prevent crystallization in the urinary tract.
$0.003BPart D
LOE Approaching0mo to LOENiche rare-disease product with minimal commercial footprint ($3M Part D spend, 512 claims in 2023) and approaching loss of exclusivity—expect small, specialized team focused on patient retention and early generic mitigation.
Mechanism of Action
Cystine Disulfide Reduction
Pharmacologic Class:
Reducing and Complexing Thiol
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
THIOLA offers limited career growth in terms of job openings (zero linked vacancies) and is best suited for professionals seeking deep expertise in rare diseases, patient-centric commercial strategies, and niche-market operations. Joining this team requires acceptance of small-scale impact and imminent LOE challenges, with career advancement likely requiring lateral moves to higher-growth products post-LOE.
Brand Manager
Worked on THIOLA at Mission Therapeutics? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.